Get the Stockscreener App
9.88
6.81%
0.63
After Hours:
9.73
-0.15
-1.52%
Fibrogen Inc stock is traded at $9.88, with a volume of 68,457.
It is up +6.81% in the last 24 hours and up +38.18% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$9.25
Open:
$9.38
24h Volume:
68,457
Relative Volume:
1.39
Market Cap:
$39.93M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.372
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
+39.06%
1M Performance:
+38.18%
6M Performance:
-24.12%
1Y Performance:
+1.33%
1-Day Range:
$9.25
$9.9323
1-Week Range:
$7.18
$10.10
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
9.88 | 37.39M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FibroGen, Inc. (NASDAQ:FGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
FibroGen’s Strategic Moves and Financial Outlook - The Globe and Mail
FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances - MSN
FibroGen's Robust Finances and Promising Pipeline Earn Analyst's Buy Rating - AInvest
FibroGen Inc. Reports Q2 2025 Earnings: Strategic Moves, Cost Reductions, and Positive Clinical Updates - AInvest
FibroGen: Q2 Earnings Snapshot - New Haven Register
Fibrogen 2025 Q2 Earnings Record Net Income and Strong Revenue Growth - AInvest
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... - Yahoo Finance
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... By GuruFocus - Investing.com Canada
FibroGen's Strategic Pivot: China Exit and FG-3246's Oncology Promise Fuel Undervalued Biotech Opportunity - AInvest
FibroGen's 2025 Q2: Unraveling Key Contradictions in Roxadustat and FG-3246 Clinical Trial Strategies - AInvest
FibroGen's Q2 2025 Earnings Miss: A Catalyst for Long-Term Value or a Warning Signal? - AInvest
Transcript : FibroGen, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
FibroGen Q2 2025 slides: China sale extends runway amid clinical progress - Investing.com Canada
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
FibroGen's Strategic Turnaround and Financial Resilience: A Path to Value Recovery? - AInvest
FibroGen Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: FibroGen Q2 2025 revenue falls short, stock drops - Investing.com
FibroGen Inc earnings missed by $1.79, revenue fell short of estimates - Investing.com Nigeria
FibroGen's Financial Challenges and Catalyst-Driven Turnaround Potential - AInvest
FibroGen Secures $210M China Deal with AstraZeneca, Advances Cancer Drug Trials - Stock Titan
Fibrogen FGEN 2025Q2 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
FibroGen shares surge on FDA support for anemia drug in MDS patients - MSN
Is FibroGen Inc. affected by consumer sentimentRocket Return Picks - thegnnews.com
FibroGen Q2 Earnings: Analysts Predict Significant Decline, 2,770% Upside Potential - AInvest
Uncovering Potential: FibroGen's Earnings Preview - 富途牛牛
FibroGen Inc expected to post a loss of $2.31 a shareEarnings Preview - TradingView
FibroGen shares rise 11.75% intraday after positive FDA meeting for roxadustat Phase 3 trial. - AInvest
Fibrogen: HC Wainwright Raises PT to $43 from $10, Maintains Buy Rating - AInvest
FibroGen stock surges after FDA feedback on roxadustat for MDS anemia - Investing.com India
FibroGen advances roxadustat for anemia in myelodysplastic syndromes By Investing.com - Investing.com Nigeria
FibroGen advances roxadustat for anemia in myelodysplastic syndromes - Investing.com
FibroGen Announces Positive Type C Meeting with the FDA for - GlobeNewswire
FDA Green-Lights FibroGen's Novel Oral Treatment for MDS Anemia: 5x Better Than Placebo - Stock Titan
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - MSN
FibroGen to Report Second Quarter 2025 Financial Results - The Manila Times
FibroGen Inc. Forms Bullish Flag — Upside AheadInvestment Plan With Growth Optimization Finalized - beatles.ru
How does FibroGen Inc. compare to its industry peersHigh-yield growth strategies - Jammu Links News
How volatile is FibroGen Inc. stock compared to the marketCapitalize on market trends with confidence - Jammu Links News
What is the dividend policy of FibroGen Inc. stockInvest confidently with professional guidance - Jammu Links News
Is FibroGen Inc. a good long term investmentRapidly growing investment returns - Jammu Links News
How does FibroGen Inc. generate profit in a changing economyGet exclusive access to premium stock research - Jammu Links News
What institutional investors are buying FibroGen Inc. stockCapitalize on momentum-driven stocks - Jammu Links News
What are analysts’ price targets for FibroGen Inc. in the next 12 monthsLightning-fast capital gains - Jammu Links News
Should I hold or sell FibroGen Inc. stock in 2025Get real-time updates on market trends - Jammu Links News
What are the latest earnings results for FibroGen Inc.Consistent triple-digit returns - Jammu Links News
What is the risk reward ratio of investing in FibroGen Inc. stockRealize exceptional returns through smart trading - Jammu Links News
How strong is FibroGen Inc. company’s balance sheetCapitalize on market shifts with expert advice - Jammu Links News
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):